C019199 / Fujian Haixi New Pharmaceutical  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
C019199 / Fujian Haixi New Pharmaceutical
NCT06220318: Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Recruiting
1/2
155
RoW
C019199, C019199 Tablets, Sintilimab, IBI308
Fujian Haixi Pharmaceuticals Co., Ltd.
Solid Tumor
08/26
08/26

Download Options